CHD prevention in clinical practice

Lancet

Volumn 348, Issue SUPPL.1, 1996, Pages

  Pyörälä, Kalevi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; ECONOMICS; ENVIRONMENTAL FACTOR; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SOCIAL ASPECT;

EID: 0029804471     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)98009-5     Document Type: Article

References (7)

1. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
2. Prevention of coronary heart disease. Report of a WHO Expert Committee. WHO Tech Rep Ser 678. Geneva: WHO, 1982.
3. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995. J Am Coll Cardiol 1996; 27: 957-1047.
4. Anderson KM, Wilsson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356-62.
5. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-54.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
7. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.